DB-1303/BNT323A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Sponsor:

DualityBio Inc.

Code:

NCT05150691

Conditions

HER2-positive Advanced Solid Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

DB-1303/BNT323

Pertuzumab Injection

Ritonavir

Itraconazole

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-21. This information was provided to ClinicalTrials.gov by DualityBio Inc. on 2025-04-09.